storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Biotechniques Laboratory electrophoresis demonstration, from the University of Utah's Genetic Science Learning Center Discontinuous native protein gel electrophoresis[link removed] Drinking straw electrophoresis How to run a DNA or RNA gel Animation of gel analysis of DNA restriction Step by step photos of running a gel and extracting DNA A typical method from wikiversity
== Uses == PPG is used in many polyurethane formulations. Synthesis of waterborne polymers has been a feature with this substance. As the basic building block is propylene oxide, there are 3 carbons per oxygen on the backbone. This confers some degree of water miscibility though not as good as ethylene oxide-based molecules. It is used to synthesize the epoxy reactive diluent and flexibilizer, Poly(propylene glycol) diglycidyl ether. Another use of PPG is as a surfactant, wetting agent and dispersant in leather finishing. PPG is also employed as a reference and calibrant in mass spectrometry and HPLC. PPG and derivatives may be used as defoamers in drilling and other applications. It is also used as a primary ingredient in the making of paintballs. It has been evaluated as a corrosion inhibitor.
Despite a rally on January 15 on news of lower unemployment insurance claims, the Dow Jones, the Nasdaq, and the S&P 500 closed just below their opening bell valuations on January 16 and finished the week at a loss upon news that Trump suggested that the most likely candidate to replace Powell as Federal Reserve Chair had changed and threats by Trump to impose import tariffs on countries that oppose the United States acquiring Greenland. Over the same two days, the dollar strengthened, gold prices fell, and yields on 2-year and 10-year Treasury notes rose. As indicated by the weakening of the U.S. dollar on its exchange rates, the precious metals price increases, and the rising yields and steepening yield curve on Treasury notes in the bond market over the week following Powell's announcement, market analysts have observed that the investigation and potential loss of the Federal Reserve's independence (along with the geopolitical risks) indicates higher long-term inflation expectations by investors and has reinforced interest for greater global diversification of investment holdings and away from U.S. assets. JPMorgan Chase CEO Jamie Dimon and BNY CEO Robin Vince both criticized the investigation, arguing that undermining the Federal Reserve's independence would raise inflation expectations, increase interest rates in the long-term, and undermine the functioning of the bond market.
In the MPG model, the pore is formed by a b-barrel structure, whereas the Pep-1 is associated with helices. In addition, strong hydrophobic phospholipid-peptide interactions have been discovered in both models. In the two peptide models, the folded parts of the carrier molecule correlate to the hydrophobic domain, although the rest of the molecule remains unstructured.
Sources: en.wikipedia.org
=== Youth levels === Townsend represented England at under-16, under-17 and under-19 level. He played three times for the under-16s between 2006 and 2007, making his debut in a 1–1 draw away with Wales on 20 October 2006 and his last appearance in a 2–0 away loss to Germany in April 2007. He scored twice on his under-17 debut, in a 6–1 win over Northern Ireland in August 2007, and went on to make six appearances, the last in a 0–0 draw with Portugal on 5 February 2008. Townsend's first two appearances at under-19 level came in the group stage of the 2009 European Championship; he was an unused substitute in the final, which England lost to Ukraine. He played four times in 2010, once as a starter in a friendly, and three times as a substitute in qualifiers for the 2010 competition. Townsend received his first call up to the England under-21 team in October 2012 for the Euro 2013 play-off matches against Serbia. He made his debut in the first leg as a 65th-minute substitute for Liverpool's Raheem Sterling. He also played in two U21 friendlies, in 2012 and 2013. In May 2013, Townsend was charged by The Football Association over alleged breaches of its rules on betting. He subsequently voluntarily withdrew from England's squad for the upcoming European Under-21 Championship finals. He later admitted to charges under the FA's rules for breaching football betting regulations. After a personal hearing, he was fined £18,000 and suspended for four months backdated to 23 May, with three months suspended until 1 July 2016.
=== Abnormal collagen === Abnormal collagen fibrils are often found in diabetes. Due to increased levels of lysyl oxidase, collagen increases cross-linking. This thickens the basement membrane, another hallmark of NL.
Alpha collagen is specifically designed to deliver specific ratios of α- chain peptides as building blocks. The targeted cells can process the α- chain peptides to form triple helix collagen, and replenish the collagen in the targeted site. Scientists believe that Alpha collagen can help to deliver specific ratios of peptides to benefit the targeted cells. Alpha collagen is designed to be used as a supplement for osteoarthritis, based on the theory of the different environments of the extracellular matrix (ECM). The ECM of joint cartilage comprises many classes of macromolecules; collagen (type I, II, VI, X collagen fibrils) and proteoglycans. The ratio and the proportion of collagen play an important role in the tensile and compressive strength, as well as the elasticity of the tissue. The content of collagen in cartilage is different between joints and soft tissue structures. For example, cartilage in the knee has a different structure to the ankle. Cartilage, skin, and spinal discs are subject to continuous regeneration during which anabolic and catabolic processes are in equilibrium. Any imbalance in this equilibrium between matrix degeneration and regeneration results in a decrease in the components of the ECM, and leads to loss of chondral damage. Therefore, it is important to tackle the degenerative process before the inflammatory metalloproteases set in by replenishing the collagen in the ECM. Collagen supplementation has been shown in research studies (in vitro and in vivo) to increase the thickness or volume of the cartilage tissue.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.